Screener
Alnylam Pharmaceuticals ALNY Research Services Obligation — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research Services Obligation | $(802) | $12,957 | $5,831 | $26,767 |
| C5 License Obligation | — | — | — | 21,458 |
| Regeneron Technology Transfer Obligation | — | — | — | 2,431 |
| Other license programs | 5,822 | 19,585 | 45,525 | 32,925 |
| Total | $5,020 | $32,542 | $51,356 | $83,581 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's research services obligation — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported research services obligation — total revenues of -$802K in Q2 2026.
- How has Alnylam Pharmaceuticals's research services obligation — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's research services obligation — total revenues decreased by 106.2% year-over-year, from $12.96M to -$802K.
- What is the long-term trend for Alnylam Pharmaceuticals's research services obligation — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's research services obligation — total revenues has grown at a 1.2% compound annual growth rate (CAGR), from $37.6M to $39.51M.
- What does research services obligation — total revenues mean?
- The total revenue recognized during the reporting period specifically attributable to the performance of research services obligations. This metric tracks the actual financial output generated from ongoing research collaborations or service contracts. It indicates the pace at which research milestones or service delivery requirements are being satisfied.
Ask your AI about Alnylam Pharmaceuticals's research services obligation — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude